FI962022A - 5,6-dihydropyrone derivatives as protease inhibitors and antivirals - Google Patents

5,6-dihydropyrone derivatives as protease inhibitors and antivirals Download PDF

Info

Publication number
FI962022A
FI962022A FI962022A FI962022A FI962022A FI 962022 A FI962022 A FI 962022A FI 962022 A FI962022 A FI 962022A FI 962022 A FI962022 A FI 962022A FI 962022 A FI962022 A FI 962022A
Authority
FI
Finland
Prior art keywords
antivirals
dihydropyrone derivatives
protease inhibitors
dihydropyrone
derivatives
Prior art date
Application number
FI962022A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI962022A0 (en
Inventor
Edmund L Ellsworth
Elizabeth Lunney
Bradley Dean Tait
Original Assignee
Parke Davis & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/319,820 external-priority patent/US5840751A/en
Application filed by Parke Davis & Co filed Critical Parke Davis & Co
Publication of FI962022A0 publication Critical patent/FI962022A0/en
Publication of FI962022A publication Critical patent/FI962022A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to novel 5,6-dihydropyrone derivatives and related structures which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The 5,6-dihydropyrone derivatives are useful in the development of therapies for the treatment of bacterial and viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of multifunctionalized 5,6-dihydropyrones and of related structures.
FI962022A 1993-11-19 1996-05-13 5,6-dihydropyrone derivatives as protease inhibitors and antivirals FI962022A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15544393A 1993-11-19 1993-11-19
US08/319,820 US5840751A (en) 1993-11-19 1994-10-12 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
PCT/US1994/012269 WO1995014012A1 (en) 1993-11-19 1994-10-26 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents

Publications (2)

Publication Number Publication Date
FI962022A0 FI962022A0 (en) 1996-05-13
FI962022A true FI962022A (en) 1996-07-12

Family

ID=26852338

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962022A FI962022A (en) 1993-11-19 1996-05-13 5,6-dihydropyrone derivatives as protease inhibitors and antivirals

Country Status (18)

Country Link
EP (1) EP0729464A1 (en)
JP (1) JP3684426B2 (en)
AT (1) ATE263761T1 (en)
AU (1) AU689158B2 (en)
CA (1) CA2176043A1 (en)
DE (1) DE69433705T2 (en)
DK (1) DK1142887T3 (en)
ES (1) ES2219457T3 (en)
FI (1) FI962022A (en)
HR (1) HRP940935B1 (en)
HU (1) HUT77668A (en)
IL (1) IL111674A0 (en)
NO (1) NO316172B1 (en)
NZ (1) NZ275961A (en)
PT (1) PT1142887E (en)
RU (1) RU2140917C1 (en)
SI (1) SI1142887T1 (en)
WO (1) WO1995014012A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100693944B1 (en) * 1995-08-11 2007-03-12 제논 인바이런멘탈 인코포레이티드 Vertical skein of hollow fiber membranes and method of maintaining clean fiber surfaces
US5834506A (en) * 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
HU228986B1 (en) 1997-09-11 2013-07-29 Upjohn Co Process to produce 4-hydroxy-2-oxo-pyrane derivatives useful as protease inhibitors
NZ510013A (en) * 1998-09-11 2003-11-28 Warner Lambert Co Dihydropyrones with selected heterocycles replacing the phenyls bearing polar substituents used as HIV protease inhibitors
US6288235B1 (en) 1999-04-14 2001-09-11 Ortho-Mcneil Pharmaceutical, Inc. Methods for the synthesis of highly substituted 2,4-dioxopiperidine libraries
DE10030094A1 (en) * 2000-06-19 2001-12-20 Bayer Ag New phenyl-substituted 5,6-dihydro-pyrone derivatives, useful as total or selective herbicides, insecticides, acaricides, nematocides, ectoparasiticides or antifouling agents
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DE10108471C1 (en) 2001-02-22 2002-11-21 Boehringer Ingelheim Pharma Continuous process for the preparation of 5,6-dihydro-4-hydroxy-2-pyrones
DE10108470A1 (en) * 2001-02-22 2002-09-05 Boehringer Ingelheim Pharma Process for the production of optically active dihydropyrones
US7141681B2 (en) 2001-02-22 2006-11-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Continuous process for preparing dihydropyrones
US6500963B2 (en) 2001-02-22 2002-12-31 Boehringer Ingelheim Pharma Kg Process for preparing optically active dihydropyrones
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
DOP2003000641A (en) 2002-05-10 2003-11-15 Pfizer INHIBITORS OF RNA-DEPENDENT RNA POLYMERASE OF HEPATITIS C VIRUSES AND COMPOSITIONS AND TREATMENT USED
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
CN101006092B (en) 2004-08-18 2013-04-17 辉瑞有限公司 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatment agent using the same
DE102005059469A1 (en) 2005-12-13 2007-06-14 Bayer Cropscience Ag Insecticidal compositions having improved activity
DE102006007882A1 (en) 2006-02-21 2007-08-30 Bayer Cropscience Ag New cyclic keto enol derivatives useful for controlling animal pests and/or unwanted plant growth
CA2654334C (en) * 2006-06-16 2014-06-10 Pharma Mar, S.A. Antitumoral dihydropyran-2-one compounds
WO2010102758A2 (en) 2009-03-11 2010-09-16 Bayer Cropscience Ag Halogenalkylmethylenoxy-phenyl-substituted ketoenols
DE102010008644A1 (en) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft, 13353 Cyclic ketoenols for therapy
RU2461555C1 (en) * 2011-07-07 2012-09-20 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" Method of producing 5-aryl-3-phenyl-2-oxaspiro[5,6]dodec-3-en-1-ones, exhibiting analgesic activity
DK2806741T3 (en) 2012-01-26 2020-05-18 Bayer Ip Gmbh PHENYL-SUBSTITUTED KETOENOLS TO FIGHT FISH PARASITES
CN104797567B (en) 2012-11-28 2017-06-20 住友化学株式会社 Dihydro pyrone compound and the herbicide containing it
SE539512C2 (en) * 2015-12-02 2017-10-03 Ultupharma Ab Compounds and methods of treating bacterial infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3818046A (en) * 1972-12-18 1974-06-18 Dow Chemical Co Sulfur-containing hydroxy pyrones and alkali metal salts thereof
ZA938019B (en) * 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses

Also Published As

Publication number Publication date
PT1142887E (en) 2004-08-31
NO962017D0 (en) 1996-05-15
CA2176043A1 (en) 1995-05-26
NZ275961A (en) 2001-11-30
RU2140917C1 (en) 1999-11-10
AU689158B2 (en) 1998-03-26
NO962017L (en) 1996-07-08
EP0729464A1 (en) 1996-09-04
WO1995014012A1 (en) 1995-05-26
NO316172B1 (en) 2003-12-22
HUT77668A (en) 1998-07-28
HRP940935B1 (en) 2004-08-31
JPH09505294A (en) 1997-05-27
JP3684426B2 (en) 2005-08-17
HU9601348D0 (en) 1996-07-29
SI1142887T1 (en) 2004-08-31
DK1142887T3 (en) 2004-06-21
HRP940935A2 (en) 1997-04-30
ES2219457T3 (en) 2004-12-01
DE69433705D1 (en) 2004-05-13
AU8125694A (en) 1995-06-06
DE69433705T2 (en) 2005-03-10
ATE263761T1 (en) 2004-04-15
IL111674A0 (en) 1995-01-24
FI962022A0 (en) 1996-05-13

Similar Documents

Publication Publication Date Title
FI962022A (en) 5,6-dihydropyrone derivatives as protease inhibitors and antivirals
FI962021A0 (en) 5,6-dihydropyrone derivatives as protease inhibitors and antivirals
MD960171A (en) Pyrone derivatives as protease inhibitors and antiviral agents
FI962020A (en) Pyrone derivatives as protease inhibitors and antiviral agents
WO1995014014A3 (en) Pyrone derivatives as protease inhibitors and antiviral agents